Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Nice – page 9

971 clinical trials in Nice, France across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Nice at a glance
971
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

971 trials in Nice

Open in trial search

Non-small cell lung cancer

Recruiting

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

Non-small cell lung cancer metastatic

Recruiting

A study of rilvegostomig and ramucirumab in patients with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ramucirumab
  • Sponsor:AstraZeneca AB

Neoplasm malignant

Recruiting

A study of YL201 and atezolizumab for patients with advanced solid tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Medilink Therapeutics (Suzhou) Co. Ltd.

Peripheral arterial occlusive disease+5

Recruiting

A study comparing one month versus one year of aspirin and clopidogrel treatment in patients with chronic limb-threatening ischemia after below-the-knee vascular therapy.

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Clopidogrel
  • Sponsor:Fondation Hopital Saint Joseph

Chronic kidney disease

Recruiting

Study of the effect of empagliflozin on protein levels in the urine for patients with type 2 diabetes and kidney disease.

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Centre Hospitalier Universitaire De Nice

Secondary progressive multiple sclerosis

Recruiting

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Squamous cell carcinoma of head and neck

Recruiting

A study of ficerafusp alfa and nivolumab in patients with head and neck cancer who did not respond to platinum-based chemotherapy.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Peripheral arterial occlusive disease

Recruiting

A study to evaluate the efficacy and safety of orforglipron in patients with peripheral artery disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

Chronic kidney disease+1

Recruiting

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

HIV infection

Recruiting

A study of islatravir and ulonivirine for adults with HIV who have not received previous treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Merck Sharp & Dohme LLC

Acute leukaemia

Recruiting

A study of enzomenib in adult patients with relapsed or refractory acute leukemia, including those with MLL rearrangement or NPM1 mutation.

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Sumitomo Pharma America Inc.

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Nice

What the registry says about research in the country

01 Neurological Disorders

Innovative research focusing on neurodegenerative conditions and movement disorders, including trials evaluating new treatments for Amyotrophic Lateral Sclerosis and Essential Tremor.

  • ALS Treatment Development
  • Movement Disorder Therapies
  • Multiple Sclerosis Management

Studies aim to improve quality of life and slow disease progression through targeted therapeutic approaches.

02 Autoimmune Conditions

Comprehensive research into inflammatory disorders, including studies on Psoriatic Arthritis and innovative treatments for various autoimmune conditions.

  • Psoriasis Management
  • Inflammatory Disease Therapy
  • Myasthenia Gravis Treatment

Focus on developing targeted therapies and combination treatments for better disease control.

03 Oncology Research

Advanced studies in cancer treatment, particularly focusing on head and neck cancers and innovative approaches in lung cancer therapy.

  • Head and Neck Cancer Treatments
  • Neuroendocrine Carcinomas
  • Prostate Cancer Therapy

Investigating combination therapies and targeted treatments for improved patient outcomes.

04 Gastrointestinal Disorders

Groundbreaking research in inflammatory bowel diseases, including novel approaches for Crohn's Disease and Ulcerative Colitis treatment.

  • Microbiota Transplantation
  • IBD Management
  • Novel Therapeutic Approaches

Exploring innovative therapeutic strategies and microbiome-based treatments.

05 Infectious Disease Prevention

Critical research in HIV prevention and treatment, focusing on long-acting preventive medications and innovative therapeutic approaches.

  • HIV Pre-Exposure Prophylaxis
  • Long-Acting Treatments
  • Prevention Strategies

Development of new preventive measures and treatment options for at-risk populations.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.